亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up

威尼斯人 阿扎胞苷 医学 髓系白血病 维持疗法 低甲基化剂 内科学 髓样 肿瘤科 白血病 儿科 重症监护医学 化疗 生物 基因 基因表达 DNA甲基化 慢性淋巴细胞白血病 生物化学
作者
Alexandre Bazinet,Hagop Kantarjian,Gautam Borthakur,Musa Yılmaz,Prithviraj Bose,Elias Jabbour,Yesid Alvarado,Kelly S. Chien,Naveen Pemmaraju,Koichi Takahashi,Nicholas J. Short,Naval Daver,Ghayas C. Issa,Nitin Jain,Debra Bull Linderman,Courtney D. DiNardo,Jan A. Burger,Alessandra Ferrajoli,Guillermo Montalban‐Bravo,Guillermo Garcia‐Manero
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 9005-9007 被引量:7
标识
DOI:10.1182/blood-2022-162918
摘要

Background: Relapse is the major cause of treatment failure in acute myeloid leukemia (AML). Patients with AML who are ineligible for allogeneic stem cell transplantation (SCT) have limited options to delay or prevent relapse once they have completed their initial therapy. Oral azacitidine (CC-486) has been shown to improve relapse-free survival (RFS) and overall survival (OS) in patients with AML who have achieved first complete remission (CR) after intensive chemotherapy, and is currently the only agent approved as maintenance therapy in AML. The combination of azacitidine (AZA) and venetoclax (VEN) is synergistic and highly effective in AML. To further improve outcomes in the post-remission setting, we studied the combination of low-dose IV/SQ AZA plus VEN as maintenance therapy in AML. Methods: This phase II study enrolled patients with AML ≥ 18 years, not immediately eligible for SCT, and who had achieved a first CR/CRi (regardless of measurable residual disease [MRD] status) following at least 2 cycles of intensive chemotherapy (defined as intermediate or higher dose cytarabine; cohort 1) or low-intensity therapy (defined as hypomethylating agent or low-dose cytarabine-based; cohort 2). Patients in CR2 or beyond were also eligible if positive for MRD. Patients were treated with AZA 50 mg/m2 IV/SQ on days 1-5 plus VEN 400 mg PO on days 1-14, every 28 days for up to 24 cycles. VEN duration could be reduced to 7 days in patients at high risk for cytopenias. VEN dosing was adjusted for concomitant azole antifungal use. The primary outcome was RFS (defined as enrollment to relapse or death, whichever occurred first). Secondary outcomes included OS, MRD clearance rates, and safety/toxicity. Patients becoming eligible for SCT could be taken off protocol to undergo the procedure and were censored at the time of SCT. This study was registered on ClinicalTrials.gov (NCT04062266). Results: As of July 14th, 2022, 34 patients have been enrolled (25 in cohort 1, 9 in cohort 2). The median follow-up time is 13.3 months (IQR 8.6-21.6). The baseline patient characteristics are shown in table 1. Nineteen (76%) patients had been previously exposed to VEN as part of their induction regimen. During cycle 1, 21 (62%) patients received 7 days of VEN and 13 (38%) received 14 days of VEN. The median number of cycles given is 9.5 (range 1-24). The median RFS is not reached (NR) in cohort 1 (70% at 12 months) and NR in cohort 2 (58% at 12 months). The median OS is NR in cohort 1 (95% at 12 months) and NR in cohort 2 (63% at 12 months). When stratified by ELN 2017, median RFS is NR (85% at 12 months), NR (70% at 12 months), and 4 months (23% at 12 months) for ELN favorable, intermediate, and adverse, respectively (figure 1). Eight patients have gone off protocol to receive SCT. There was no significant effect of prior venetoclax exposure on RFS or OS. Of the 7 MRD-positive patients at enrollment, 2 (29%) converted to MRD-negative while on maintenance therapy. The MRD-positive patients in our study had a high incidence of adverse prognostic factors (5/7 ELN adverse, 3/7 complex karyotypes). Of these MRD-positive patients, 3 went off study to receive SCT and remain in remission. The 4 remaining MRD-positive patients have relapsed after 1.9, 2.5, 4.0, and 6.0 months. The most common grade 3/4 adverse events were thrombocytopenia (21%), infections (21%), neutropenia (18%), and neutropenic fever (6%). Four patients (12%) required VEN dose reductions at cycle 2 for cytopenias. Seven (21%) patients died, all following relapse of AML or from SCT complications. Conclusions: With over 13 months of follow up, this is the first experience demonstrating the tolerability and feasibility of low-dose AZA plus VEN as maintenance therapy in AML. RFS and OS are encouraging, especially in the non-adverse risk ELN categories (favorable or intermediate). Further studies are needed to improve maintenance strategies in patients with ELN adverse or MRD-positive disease. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
荷兰香猪发布了新的文献求助10
5秒前
漂亮的半兰完成签到,获得积分10
24秒前
1分钟前
Heart_of_Stone完成签到 ,获得积分10
1分钟前
1分钟前
友好大树发布了新的文献求助10
1分钟前
gd完成签到 ,获得积分10
1分钟前
科研通AI65的应助被amiee采纳,获得10
1分钟前
Akim的应助被盼盼采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
科目三的应助被荷兰香猪采纳,获得10
1分钟前
1分钟前
2分钟前
不忘初鑫完成签到 ,获得积分10
2分钟前
amiee发布了新的文献求助10
2分钟前
荷兰香猪发布了新的文献求助10
2分钟前
顺心安雁完成签到,获得积分10
2分钟前
汉堡包的应助被whc采纳,获得10
2分钟前
2分钟前
科研通AI6.3的应助被聪慧亦凝采纳,获得10
2分钟前
whc发布了新的文献求助10
2分钟前
2分钟前
李爱国的应助被初景采纳,获得10
2分钟前
聪慧亦凝发布了新的文献求助10
2分钟前
动听的诗翠完成签到,获得积分10
2分钟前
虚拟的清炎完成签到 ,获得积分10
3分钟前
3分钟前
初景发布了新的文献求助10
3分钟前
充电宝的应助被荷兰香猪采纳,获得10
3分钟前
香蕉觅云的应助被蔓越莓奶酥采纳,获得30
3分钟前
沉默的樱完成签到,获得积分10
3分钟前
3分钟前
荷兰香猪发布了新的文献求助10
4分钟前
英俊的铭的应助被amiee采纳,获得10
4分钟前
xiaoshulin完成签到,获得积分10
4分钟前
勤劳的翩跹完成签到,获得积分10
4分钟前
yc发布了新的文献求助10
4分钟前
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190159
求助须知:如何正确求助?哪些是违规求助? 9577257
关于积分的说明 21852297
捐赠科研通 7788567
什么是DOI,文献DOI怎么找? 3436279
关于科研通互助平台的介绍 2560058
邀请新用户注册赠送积分活动 2482880